Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 5475

Next Previous
Drug Profile

MK 5475

Alternative Names: MK-5475

Latest Information Update: 03 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary hypertension
  • Discontinued Pulmonary arterial hypertension

Most Recent Events

  • 17 May 2025 Discontinued - Phase-II/III for Pulmonary arterial hypertension in Sweden, Belgium, United Kingdom, Turkey, Russia, Poland, Mexico, New Zealand, Italy, Israel, Greece, France, Colombia, Canada, Australia, Argentina, USA, Germany (Inhalation)
  • 17 May 2025 Discontinued - Phase-I for Pulmonary arterial hypertension in Moldova (Inhalation)
  • 17 May 2025 Adverse events data from the phase-II/III INSIGNIA-PAH trial in Pulmonary arterial hypertension presented at the 121st International Conference of the American Thoracic Society (ATS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top